List view / Grid view
22 July 2015 | By Victoria White
A Phase III study of selumetinib in combination with dacarbazine for the treatment of metastatic uveal melanoma failed to meet its primary endpoint...
22 July 2015 | By Victoria White
Bristol-Myers Squibb has announced additional Phase IIa data for BMS-955176, a novel investigational agent designed to prevent the maturation of HIV-1...
22 July 2015 | By Victoria White
NICE has recommended aflibercept solution for injection and dexamethasone implant as treatment options for some people with diabetic macular oedema...
22 July 2015 | By Victoria White
NICE has recommended the use of 3M Tegaderm CHG IV securement dressing to hold catheters in place securely, reducing the risk of catheter related infections...
21 July 2015 | By Victoria White
BioMarin has provided an update on the ABRAZO Phase 2 study of its poly ADP-ribose polymerase (PARP) inhibitor, talazoparib...
21 July 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation to BMS-663068 for the treatment of HIV-1 infection in heavily treatment-experienced adult patients...
21 July 2015 | By Victoria White
Tekmira Pharmaceuticals Corporation has announced plans to change its corporate name to Arbutus Biopharma Corporation, to be effective by 3 August 2015...
21 July 2015 | By Victoria White
The EC has granted marketing authorisation for Repatha for the treatment of patients with uncontrolled cholesterol who require additional LDL-C reduction...
21 July 2015 | By Victoria White
The global market value for genital herpes therapeutics will increase from approximately $490 million in 2013 to just under $668 million by 2023, largely driven by the introduction of therapeutic vaccines, HerpV and GEN-003, towards the end of the forecast period, says research and consulting firm GlobalData.
21 July 2015 | By Victoria White
A Phase 3 study of tozadenant in patients with Parkinson's disease experiencing levodopa related end-of-dose "wearing-off" has started...
21 July 2015 | By Victoria White
The first group of healthy volunteers have been dosed in a Phase I clinical trial assessing the safety and tolerability of an oral formulation of MGB-BP-3...
21 July 2015 | By Victoria White
The EC has approved nivolumab for the treatment of locally advanced or metastatic squamous non-small cell lung cancer after prior chemotherapy...
20 July 2015 | By Victoria White
Researchers have successfully treated patients with moderate to severe eczema using an arthritis drug recently shown to reverse two other skin conditions...
20 July 2015 | By Victoria White
Results of the first Phase 2a study of lonafarnib in patients with chronic hepatitis delta virus (HDV) infection have been published...
20 July 2015 | By Victoria White
The CheckMate -025 study evaluating Opdivo versus everolimus in patients with advanced or metastatic RCC has been stopped early as it met its endpoint...
